SLN Latest Press Releases

-- November 12, 2026 --

Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results Business Wire 8:00 AM

-- November 4, 2026 --

Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026 Business Wire 9:00 AM

-- October 22, 2026 --

Halper Sadeh LLC is Investigating Whether BWMN, HZO, SLN are Obtaining Fair Deals for their Shareholders Globe Newswire 10:29 AM

-- October 21, 2026 --

Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN Business Wire 3:35 PM

-- October 20, 2026 --

Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders? PRNewswire 12:22 PM

-- October 19, 2026 --

SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders Business Wire 9:40 AM

Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset Business Wire 8:00 AM

Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany Business Wire 8:00 AM

-- September 2, 2026 --

Silence Therapeutics to Participate in Three September Investor Conferences Business Wire 8:00 AM

-- August 14, 2026 --

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs Business Wire 4:55 PM

-- August 11, 2026 --

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering Business Wire 11:20 PM

-- August 10, 2026 --

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares Business Wire 4:01 PM

The Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major Milestones Globe Newswire 10:39 AM

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile Business Wire 7:30 AM

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results Business Wire 7:15 AM

-- August 9, 2026 --

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera Business Wire 5:00 PM

Market Data Delayed 15 Minutes